As of close of business last night, X4 Pharmaceuticals Inc’s stock clocked out at $0.88, down -4.00% from its previous closing price of $0.92. In other words, the price has decreased by -$0.0367 from its previous closing price. On the day, 1426960 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of XFOR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.81 and its Current Ratio is at 5.81. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.85.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 12 ’24 when Mostafa Adam S. sold 27,721 shares for $1.01 per share. The transaction valued at 27,973 led to the insider holds 52,500 shares of the business.
Ragan Paula sold 21,695 shares of XFOR for $21,892 on Feb 12 ’24. The President and CEO now owns 814,746 shares after completing the transaction at $1.01 per share. On Feb 12 ’24, another insider, DiBiase Mary, who serves as the Chief Operating Officer of the company, sold 3,683 shares for $1.01 each. As a result, the insider received 3,709 and left with 307,161 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 148.96M and an Enterprise Value of 65.56M.
Stock Price History:
Over the past 52 weeks, XFOR has reached a high of $2.58, while it has fallen to a 52-week low of $0.57. The 50-Day Moving Average of the stock is 0.8673, while the 200-Day Moving Average is calculated to be 1.1988.
Shares Statistics:
It appears that XFOR traded 1.78M shares on average per day over the past three months and 1.62M shares per day over the past ten days. A total of 121.67M shares are outstanding, with a floating share count of 121.16M. Insiders hold about 27.57% of the company’s shares, while institutions hold 36.09% stake in the company. Shares short for XFOR as of Feb 15, 2024 were 13.23M with a Short Ratio of 7.44, compared to 11.99M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.91% and a Short% of Float of 7.93%.
Earnings Estimates
As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.17, while EPS last year was -$0.29. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.14 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.62 and -$0.65 for the fiscal current year, implying an average EPS of -$0.63. EPS for the following year is -$0.45, with 7 analysts recommending between -$0.06 and -$0.69.
